Promising Preclinical Lung Cancer Studies
In preclinical studies with mice harbouring solid lung and metastatic cancer, mice survival increased dramatically and tumor growth was inhibited.
Preclinical Lung Cancer in animal models
The graph depicts the decreasing tumor volume and increasing survival curve of mice with lung cancer treated with NADAV (purple) compared with untreated lung cancer mice (yellow).
Encouraging preclinical studies conducted on melanoma
Furthermore, NADAV was also shown to have a greater killing effect (number of apoptotic cells) on melanoma cells compared with conventional chemotherapies such as Cisplatin, Carboplatin, Etoposide and Oxaliplatin.
The graph demonstrates that in both cultures with early (EAR) and advanced (ADV) stages of melanoma, patient cells were more susceptible to the killing effect of NADAV than the chemotherapies, with the effect greatest in the advanced stages.